bis
Market Research Report

A quick peek into the report

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market - A Global and Regional Analysis

Focus on Drug Class, Therapy Type, and Region - Analysis and Forecast, 2025-2035

 
Some Faq's

Frequently Asked Questions

Ans: The global epidermal growth factor receptor-non small cell lung cancer market was valued at approximately $XX million in 2023 and is expected to reach $XX million by 2035, exhibiting a compound annual growth rate (CAGR) of approx. XX% from 2025 to 2035.

Ans: The global epidermal growth factor receptor-non small cell lung cancer market is led by prominent pharmaceutical companies such as AbbVie Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc. and Takeda Pharmaceutical Company Limited.

Trends:
•    Dominance of third-generation EGFR-TKIs
•    Expansion into adjuvant and neoadjuvant settings
•    Emergence of novel therapeutic agents
•    Integration of immunotherapy and combination regimens
•    Advancements in companion diagnostics
Driver:
•    High prevalence of EGFR mutations
•    Clinical efficacy of targeted therapies
•    Regulatory approvals and expanding indications
•    Growing investment in oncology research

Acquired resistance to EGFR tyrosine kinase inhibitors (TKIs)
•    High treatment costs
•    Limited access to advanced diagnostic tools
•    Regulatory and manufacturing challenges

•    Advancements in targeted therapies
•    Expansion into adjuvant and neoadjuvant settings
•    Integration of immunotherapy and combination regimens
•    Advancements in companion diagnostics 
•    Regulatory support for rare disease therapies